Boothbay Fund Management, LLC 89bio, Inc. Transaction History

Boothbay Fund Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$10.48 - $16.94 $814,882 - $1.32 Million	-77,756 Reduced 87.83%	10,779 $164,000
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $291,318 - $671,825	52,775 Added 147.58%	88,535 $1.13 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $107,995 - $250,320	35,760 New	35,760 $207,000
Q4 2020 Feb 12, 2021	SELL	$23.16 - $28.08 $905,648 - $1.1 Million	-39,104 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $951,791 - $1.52 Million	39,104 New	39,104 $1 Million

162

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $293M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.